NeOnc Technologies announces NuroMENA Holdings' incorporation, enabling a $50 million investment from Quazar for CNS cancer therapies in MENA.
Quiver AI Summary
NeOnc Technologies Holdings, Inc. has announced the official incorporation of NuroMENA Holdings Ltd. in the Abu Dhabi Global Market, facilitating a $50 million investment from Quazar Investment. This partnership aims to launch NeOnc's innovative therapies for central nervous system cancers in the MENA region, enhancing the development of their clinical programs NEO212 and NEO100. NeOnc’s Executive Chairman, Amir Heshmatpour, emphasized the significance of this milestone in delivering vital therapies, while Quazar’s CEO, Waleed K. Al Ali, expressed pride in supporting advances in biotechnology in the UAE. NuroMENA will oversee clinical operations and strategic initiatives in the region, with joint governance from both companies supporting their shared goal of improving CNS treatment outcomes.
Potential Positives
- The incorporation of NuroMENA Holdings Ltd. marks a significant regulatory milestone, enabling the company to establish a foothold for clinical operations in the MENA region.
- The finalized $50 million investment from Quazar Investment strengthens NeOnc's financial position and supports the development of its therapeutic pipeline for CNS cancers.
- This partnership is positioned to enhance NeOnc's visibility and credibility in a critical healthcare market, potentially leading to greater collaboration opportunities and market expansion.
- Quazar Investment’s involvement brings additional strategic governance and oversight, which could accelerate the launch of innovative CNS therapies across the region.
Potential Negatives
- The press release highlights a significant investment partnership; however, it also indicates that a majority of NuroMENA Holdings Ltd. will be controlled by Quazar Investment, which may raise concerns about NeOnc's level of control and influence over its own operations in the region.
- The announcement comes at a time when the biotechnology industry faces heightened scrutiny and challenges in clinical trials, particularly for CNS therapies, potentially impacting investor confidence in NeOnc’s pipeline and strategies.
- The focus on the UAE and MENA region may limit NeOnc's market potential and diversification, potentially exposing the company to regional economic instability or market-specific risks.
FAQ
What is NuroMENA Holdings Ltd.?
NuroMENA Holdings Ltd. is a UAE-based subsidiary of NeOnc Technologies focused on CNS therapies in the MENA region.
What is the significance of the $50 million investment?
The $50 million investment from Quazar Investment will support NeOnc’s CNS platform launch across the MENA region.
Who are the key executives involved in this partnership?
Amir Heshmatpour, Executive Chairman of NeOnc, and Waleed K. Al Ali, Chairman and CEO of Quazar Investment, lead this collaboration.
When was NuroMENA officially incorporated?
NuroMENA was officially incorporated under the Abu Dhabi Global Market on August 6, 2025.
What are the main goals of NeOnc Technologies?
NeOnc aims to develop innovative therapies for CNS cancers, focusing on improving outcomes in difficult-to-treat oncological areas.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
$NTHI Insider Trading Activity
$NTHI insiders have traded $NTHI stock on the open market 16 times in the past 6 months. Of those trades, 16 have been purchases and 0 have been sales.
Here’s a breakdown of recent trading of $NTHI stock by insiders over the last 6 months:
- AMIR F HESHMATPOUR (President) has made 7 purchases buying 12,000 shares for an estimated $121,299 and 0 sales.
- THOMAS C CHEN (CEO) has made 3 purchases buying 5,868 shares for an estimated $42,802 and 0 sales.
- JIM DELSHAD has made 3 purchases buying 5,100 shares for an estimated $37,258 and 0 sales.
- KEITHLY GARNETT (CFO) has made 3 purchases buying 900 shares for an estimated $6,527 and 0 sales.
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
Full Release
Quazar Chairman and Executive Team with NeOnc’s Executive’s and Directors at Quazar’s Headquarters in Dubai.
CALABASAS, Calif. and ABU DHABI, United Arab Emirates, Aug. 11, 2025 (GLOBE NEWSWIRE) -- NeOnc Technologies Holdings, Inc. (NASDAQ: NTHI), a multi–Phase 2 clinical-stage biotechnology company pioneering therapies for central nervous system (CNS) cancers, announced today the official incorporation of NuroMENA Holdings Ltd. by the Abu Dhabi Global Market (ADGM). With this regulatory milestone completed, all contingencies have now been met to finalize the previously announced $50 million cornerstone investment effort led by Quazar Investment into NuroMENA Holdings Ltd.
This strategic partnership will support the launch of NeOnc’s innovative CNS platform across the MENA region and help to accelerate development of its therapeutic pipeline, including the NEO212 and NEO100 clinical programs.
“We view this as a defining moment for NeOnc and a major validation of our global vision,” said Amir Heshmatpour, Executive Chairman and President of NeOnc Technologies. “With the finalization of NuroMENA’s incorporation and the support of Quazar Investment, we are now fully equipped ot continue our goals toward delivering life-saving therapies to a region in urgent need of innovation. This partnership not only brings capital it brings conviction, commitment, and alignment on purpose.”
Waleed K. Al Ali, Chairman and CEO of Quazar Investment, added: “We are proud to partner with NeOnc to bring cutting edge biotechnology to the UAE and beyond. With NuroMENA now officially formed under ADGM, we are positioned to assist NeOnc with efforts to transform the landscape of brain cancer and CNS treatment across the region. This is just the beginning.”
About NuroMENA Holdings Ltd.
NuroMENA is a UAE-based subsidiary of NeOnc Technologies Holdings, Inc., established as part of the UAE structure to oversee regional clinical operations, partnerships, and innovation in the Middle East and North Africa. Upon closing of the $50 million investment and execution of the change of control, NuroMENA will be majority-controlled by Quazar Investment, with joint governance oversight and strategic alignment between NeOnc and Quazar to assist accelerating breakthrough CNS therapies across the region. NuroMENA was officially incorporated under ADGM on August 6, 2025.
About NeOnc Technologies Holdings, Inc. (NASDAQ: NTHI)
NeOnc Technologies is a multi–Phase 2 clinical-stage biotechnology company focused on novel therapies for brain cancer and other CNS disorders. With a robust IP portfolio and strong academic collaborations, NeOnc is committed to transforming outcomes in one of the hardest-to-treat areas of oncology.
About Quazar Investment
Quazar Investment is a leading strategic investment firm headquartered in Abu Dhabi, managing over $3.3 billion in assets under management (AUM). Backed by key partnerships with the UAE Government, Quazar focuses on transformative investments in biotechnology, healthcare, and next-generation infrastructure across the MENA region and globally.
“NEO100” and NEO “212” are registered trademarks of NeOnc Technologies Holdings, Inc.
Company Contact:
i
[email protected]
Investor Contact:
James Carbonara
Hayden IR
(646)-755-7412
[email protected]
A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/6522c372-115c-4a62-a755-8faa7119124f
